Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

# **144: Filer Information**

Filer CIK0002004379Filer CCCXXXXXXXIs this a LIVE or TEST Filing?IVE TESTSubmission Contact InformationIVE

Name Phone E-Mail Address

# **144: Issuer Information**

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

### **144: Securities Information**

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, nominal value EUR 0.12 per share	Cooperatieve Rabobank U.A. Croeselaan 18 Utrecht P7 3521CB	45000	778050.00	90015357	10/01/2024	Nasdaq Global Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

# **144: Securities To Be Sold**

Title of the Class Date you Nat Acquired Acqu Tran

Nature of N Acquisition Transaction

Name of Person Is from Whom this Acquired

Is Date . this Donor Acquired

Amount of Securities Acquired

Officer

of Date of es Payment Nature of Payment \*

NewAmsterdam Pharma Co N.V. 001-41562 GOOIMEER 2-35 NARRDEN NETHERLANDS 1411 DC 35 206 2971 Kooij Louise Frederika

		Gift?		
Ordinary shares, nominal value EUR 0.12 09/30/2024 Option Exercise per share	NewAmsterdam Pharma Company N.V.		45000	09/27/2024 Cash

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

a

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Nothing to Report

### 144: Remarks and Signature

Remarks Date of Notice *ATTENTION*:

10/01/2024

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature /s/ Louise Kooij

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)